Essential Health Benefits Standard Specialty PA and QL List July 2016
|
|
- Matthew Grant
- 5 years ago
- Views:
Transcription
1 Anti-infectives Antiretrovirals, HIV SELZENTRY (maraviroc) Cardiology Antilipemic Pulmonary Arterial Hypertension Central Nervous System Anticonvulsants Depressant Neurotoxins Parkinson's Sleep Disorder Dermatology JUXTAPID (lomitapide) PRALUENT (alirocumab) REPATHA (evolocumab) ADCIRCA (tadalafil) ADEMPAS (riociguat) FLOLAN (epoprostenol) LETAIRIS (ambrisentan) OPSUMIT (macitentan) ORENITRAM (treprostinil diolamine) REMODULIN (treprostinil) REVATIO (sildenafil) Soln REVATIO (sildenafil) Tabs TRACLEER (bosentan) TYVASO (treprostinil) UPTRAVI (selexipag) UPTRAVI (selexipag) Pack VELETRI (epoprostenol) VENTAVIS (iloprost) SABRIL (vigabatrin) pack XYREM (sodium oxybate) BOTOX (onabotulinumtoxina) DYSPORT (abobotulinumtoxina) MYOBLOC (rimabotulinumtoxinb) XEOMIN (incobotulinumtoxina) APOKYN (apomorphine) HETLIOZ (tasimelteon) Alkylating Agents VALCHLOR (mechlorethamine) Gel Electrolyte & Renal Agents 2 syringes/28 days 3 syringes/28 days 3 tabs/day Updated 07/01/2016 Page 1 of 6 3 tabs/day 1 ampule/day 2 packs/year 9 ampules/day 3 bottles (540 ml)/30 days 20 cartridges/30 days 1 cap/day Diuretics KEVEYIS (dichlorphenamide) 4 tabs/day Endocrinology & Metabolism Gonadotropins ELIGARD (leuprolide) 22.5 mg (3-month) 1 injection/84 days ELIGARD (leuprolide) 30 mg (4-month) ELIGARD (leuprolide) 45 mg (6-month) ELIGARD (leuprolide) 7.5 mg (1-month) FIRMAGON (degarelix) 120 mg FIRMAGON (degarelix) 80 mg LUPRON (leuprolide) 1 mg/0.2 ml LUPRON DEPOT (leuprolide) 3.75 mg & 7.5 mg (1-month) LUPRON DEPOT-PED (leuprolide) SUPPRELIN LA (histrelin acetate) 1 injection/112 days 1 injection/168 days 1 injection/28 days 2 vials/year 1 vial/28 days 1 kit/365 days
2 Endocrinology & Metabolism Gonadotropins Growth Hormones and Related Therapy Hormone Modifiers Osteoporosis Somatostatins Enzyme-Related Alpha-1 proteinase inhibitor Cystine-depleting Agents Enzyme Replacement Enzyme, Gout Phenylketonuria Treatment Agents Gastroenterology TRELSTAR (triptorelin) 22.5 mg (6-month) TRELSTAR DEPOT (triptorelin) 3.75 mg (1-month) TRELSTAR LA (triptorelin) mg (3-month) VANTAS (histrelin) EGRIFTA (tesamorelin) 1 mg EGRIFTA (tesamorelin) 2 mg NORDITROPIN (somatropin) NUTROPIN (somatropin) NUTROPIN AQ (somatropin) SEROSTIM (somatropin) ZORBTIVE (somatropin) INCRELEX (mecasermin) SOMAVERT (pegvisomant) MYALEPT (metreleptin) H.P. ACTHAR (corticotropin) PROLIA (denosumab) SANDOSTATIN (octreotide) SANDOSTATIN LAR (octreotide) SIGNIFOR (pasireotide) SOMATULINE DEPOT (lanreotide) ARALAST (alpha-1 proteinase inhibitor) GLASSIA (alpha-1 proteinase inhibitor) PROLASTIN (alpha-1 proteinase inhibitor) ZEMAIRA (alpha-1 proteinase inhibitor) CYSTARAN (cysteamine) PROCYSBI (cysteamine bitartrate) ALDURAZYME (laronidase) CEREZYME (imiglucerase) ELAPRASE (idursulfase) ELELYSO (taliglucerase) FABRAZYME (agalsidase beta) KANUMA (sebelipase alfa) LUMIZYME (alglucosidase alfa) MYOZYME (alglucosidase alfa) NAGLAZYME (galsulfase) RAVICTI (glycerol phenylbutyrate) STRENSIQ (asfotase alfa) VIMIZIM (elosulfase) VPRIV (velaglucerase) ZAVESCA (miglustat) KRYSTEXXA (pegloticase) KUVAN (sapropterin) Short Bowel Syndrome GATTEX (teduglutide) 1 injection/168 days 1 injection/28 days 1 injection/84 days 1 implant/year 2 vials (1 mg each)/day 1 vial (2 mg each)/day 2 syringes/year 2 ampules/day 4 bottles/28 days Updated 07/01/2016 Page 2 of 6
3 Immunology Hematopoietic Agents Hepatitis C Agents Immune Globulins Immunomodulators Interleukins Multiple Sclerosis ARANESP (darbepoetin alfa) EPOGEN (epoetin alfa) LEUKINE (sargramostim) MOZOBIL (plerixafor) NEULASTA (pegfilgrastim) NEUMEGA (oprelvekin) NEUPOGEN (filgrastim) NPLATE (romiplostim) PROCRIT (epoetin alfa) PROMACTA (eltrombopag) SOLIRIS (eculizumab) DAKLINZA (daclatasvir dihydrochloride) DAKLINZA (daclatasvir dihydrochloride) 30 mg HARVONI (ledipasvir-sofosbuvir) PEGASYS (peginterferon alfa-2a) PEG-INTRON (peginterferon alfa-2b) SOVALDI (sofosbuvir) ZEPATIER (elbasvir-grazoprevir) BIVIGAM (immune globulin) CARIMUNE (immune globulin) CYTOGAM (cytomegalovirus immune globulin) FLEBOGAMMA (immune globulin) FLEBOGAMMA DIF (immune globulin) GAMASTAN (immune globulin) GAMMAGARD (immune globulin) GAMMAKED (immune globulin) GAMMAPLEX (immune globulin) GAMUNEX (immune globulin) GAMUNEX-C (immune globulin) HIZENTRA (immune globulin) OCTAGAM (immune globulin) PRIVIGEN (immune globulin) CIMZIA (certolizumab) ENBREL (etanercept) HUMIRA (adalimumab) KINERET (anakinra) ORENCIA (abatacept) REMICADE (infliximab) SIMPONI (golimumab) SIMPONI ARIA (golimumab) ARCALYST (rilonacept) ILARIS (canakinumab) BENLYSTA (belimumab) AMPYRA (dalfampridine) AUBAGIO (teriflunomide) AVONEX (interferon beta-1a) BETASERON (interferon beta-1b) COPAXONE (glatiramer) 8 vials (9.6 ml) per transplant 3 tabs/day 2 vials/4 weeks 1 kit (4 syringes)/28 days 1 package/28 days 1 kit/30 days Updated 07/01/2016 Page 3 of 6
4 Immunology Multiple Sclerosis Transplant Collagenase Diagnostic Movement Disorder Agents Toxicology Viscosupplements Obstetrics & Gynecology GILENYA (fingolimod) GLATOPA (glatiramer) SOSY 20 mg/ml LEMTRADA (alemtuzumab) NOVANTRONE (mitoxantrone) REBIF (interferon beta-1a) REBIF (interferon beta-1a) Starter Pack TECFIDERA (dimethyl fumarate) TECFIDERA (dimethyl fumarate) Starter Pack TYSABRI (natalizumab) NULOJIX (belatacept) ZORTRESS (everolimus) XIAFLEX (collagenase clostridium histolyticum) THYROGEN (thyrotropin alfa) XENAZINE (tetrabenazine) EXJADE (deferasirox) FERRIPROX (deferiprone) Tabs JADENU (deferasirox) MONOVISC (hyaluronan) ORTHOVISC (sodium hyaluronate) SYNVISC (sodium hyaluronate) SYNVISC-ONE (sodium hyaluronate) Hormone Replacement MAKENA (hydroxyprogesterone caproate) Oncology (Injectable) Antimicrotubular Interferons Kinase and Molecular Target Inhibitors Monoclonal Antibody HALAVEN (eribulin) JEVTANA (cabazitaxel) INTRON A (interferon alfa-2b) SYLATRON (peginterferon alfa-2b) KYPROLIS (carfilzomib) PORTRAZZA (necitumumab) Soln VELCADE (bortezomib) ZALTRAP (ziv-aflibercept) DACOGEN (decitabine) ISTODAX (romidepsin) SYNRIBO (omacetaxine) ADCETRIS (brentuximab) ARZERRA (ofatumumab) BLINCYTO (blinatumomab) DARZALEX (daratumumab) Soln EMPLICITI (elotuzumab) Solr GAZYVA (obinutuzumab) HERCEPTIN (trastuzumab) KADCYLA (ado-trastuzumab emtansine) OPDIVO (nivolumab) 1 cap/day 1 kit/30 days 12 syringes/28 days 1 starter pack/year 2 caps/day 1 starter pack/year 1 injection /28 days 2 vials/21 days Updated 07/01/2016 Page 4 of 6
5 Oncology (Injectable) PERJETA (pertuzumab) RITUXAN (rituximab) XGEVA (denosumab) YERVOY (ipilimumab) Oncology (Oral) Alkylating Agents Antiandrogen Kinase and Molecular Target Inhibitors TEMODAR (temozolomide) XTANDI (enzalutamide ) ZYTIGA (abiraterone) AFINITOR (everolimus) AFINITOR DISPERZ (everolimus) BOSULIF (bosutinib) CAPRELSA (vandetanib) 100 mg CAPRELSA (vandetanib) 300 mg COMETRIQ (carbozantinib) COTELLIC (cobimetnib) 63 tabs/28 days ERIVEDGE (vismodegib) FARYDAK (panobinostat) 6 caps/ 21 days GILOTRIF (afatinib) GLEEVEC (imatinib) IBRANCE (palbociclib) ICLUSIG (ponatinib) 15 mg ICLUSIG (ponatinib) 45 mg IMBRUVICA (ibrutinib) INLYTA (axitinib) JAKAFI (ruxolitinib) JAKAFI (ruxolitinib) 10 mg LENVIMA (lenvatinib) LYNPARZA (olaparib) MEKINIST (trametinib) NEXAVAR (sorafenib) NINLARO (ixazomib) SPRYCEL (dasatinib) 3 caps/28 days STIVARGA (regorafenib) SUTENT (sunitinib) TAFINLAR (dabrafenib) TAGRISSO (osimertinib) TARCEVA (erlotinib) TASIGNA (nilotinib) 3 tabs/day TYKERB (lapatinib) VOTRIENT (pazopanib) XALKORI (crizotinib) ZELBORAF (vemurafenib) ZYDELIG (idelalisib) ZYKADIA (ceritinib) LONSURF (trifluridine-tipiracil) MG 100 tabs/28 days Updated 07/01/2016 Page 5 of 6
6 Oncology (Oral) LONSURF (trifluridine-tipiracil) MG TARGRETIN (bexarotene) caps 80 tabs/28 days TARGRETIN (bexarotene) Gel XELODA (capecitabine) ZOLINZA (vorinostat) Thalidomide-related Agents POMALYST (pomalidomide) REVLIMID (lenalidomide) THALOMID (thalidomide) Respiratory Asthma/COPD NUCALA (mepolizumab) 1 vial/28 days XOLAIR (omalizumab) Cystic fibrosis CAYSTON (aztreonam) KALYDECO (ivacaftor) KALYDECO (ivacaftor) Packs PULMOZYME (dornase alfa) Pulmonary Fibrosis ESBRIET (pirfenidone) OFEV (nintedanib) Respiratory Syncytial Virus Agents SYNAGIS (palivizumab) Quantity Limit Programs Therapeutic Category Drug Name Dispensing Limit Anti-infectives Antiretrovirals, Hepatitis B Antiretrovirals, HIV Cardiology BARACLUDE (entecavir) BARACLUDE (entecavir) Soln FUZEON (enfuvirtide) 630 ml/30days 60 vials or 1 kit/30 days Anticoagulants, LMWH ARIXTRA (fondaparinux) 35 days supply/180 days Endocrinology & Metabolism Gonadotropins Vasopressin Antagonist Obstetrics & Gynecology FRAGMIN (dalteparin) LOVENOX (enoxaparin) ZOLADEX (goserelin) 10.8 mg ZOLADEX (goserelin) 3.6 mg SAMSCA (tolvaptan) 35 days supply/180 days 35 days supply/180 days 1 injection/84 days 1 injection/28 days 30 days supply/60 days Hormone Replacement CRINONE (progesterone) 8% 60 applicators/30 days Respiratory Cystic fibrosis TOBI PODHALER (tobramycin) 1 package (224 tabs)/56 days PLEASE NOTE: This drug list is subject to periodic updates and may not be all inclusive. Drugs affected include both brand and generic where applicable and includes all dosage formulations unless otherwise specifically notated. If a new drug is approved and falls into one of the targeted PA categories, the new drug may automatically be added to this list. Quantity limits may also apply. *Quantity limits are built into the PA criteria approval and varies based on indication and/or other clinical factors. Updated 07/01/2016 Page 6 of 6
7 Specialty Pharmacy Drug List - Medical Code Drug Name Generic Name Benefit J9264 Abraxane paclitaxel Medical J3262 Actemra/tocilizumab Anti-inflammatory Medical C9287 Adcetris brentuximab vedotin Medical J1931 ALDURAZYME/laronidase Enzymes Medical J9305 Alimta pemetrexed Medical J2469 Aloxi palonosetron Medical J0256 Aralast* Alpha-1 Medical J9035 Avastin bevacizumab Medical J1556 BIVIGAM IVIG/immunizing Medical J0585 Botox A onabotulinum toxin toxin A Medical J0586 Botox A (Dysport) abobotulinum toxin A Medical J0588 Botox A (Xeomin) incobotulinum toxin A Medical J0587 Botox B (Myobloc) rimabotulinum toxin B Medical J1566 CARIMUNE IVIG/immunizing Medical J0205 CEREDASE/alglucerase Enzymes Medical J1786 CEREZYME/imiglucerase Enzymes Medical J1743 ELAPRASE/idursulfase Enzymes Medical J9055 Erbitux cetuximab Medical J7323 Euflexxa Medical J0180 FABRAZYME/agalsidase Enzymes Medical
8 J1572 FLEBOGAMMA IVIG/immunizing Medical J0641 Fusilev levoleucovorin Medical J1460 GAMASTAN S/D IVIG/immunizing Medical J1569 GAMMAGARD LIQUID IVIG/immunizing Medical J1566 GAMMAGARD S/D IVIG/immunizing Medical J1561 GAMMAKED IVIG/immunizing Medical J1557 GAMMAPLEX IVIG/immunizing Medical J1561 GAMUNEX IVIG/immunizing Medical J1561 GAMUNEX C IVIG/immunizing Medical J7326 Gel One Medical J0256 Glassia* Alpha-1 Medical J9179 Halaven eribulin mesylate Medical J9355 Herceptin trastuzumab Medical J1559 HIZENTRA IVIG/immunizing Medical J0800 HP Acthar repository corticotropin Medical J7321 Hyalgan Medical J9043 Jevtana cabazitaxel Medical J9354 Kadcyla adotrastuzumab Medical J0221 LUMIZYME/alglucosidase Enzymes Medical J0220 MYOZYME//aglucosiderase Enzymes Medical J1458 NAGLAZYME/galsulfase Enzymes Medical J1568 OCTAGAM IVIG/immunizing Medical J0129 Orencia/abatacept Anti-inflammatory Medical J7324 Orthovisc Medical C9292 Perjeta pertuzumab Medical J1459 PRIVIGEN IVIG/immunizing Medical Q2043 Provenge sipuleucel-t Medical J1745 Remicade/infliximab Anti-inflammatory Medical J9310 Rituxan rituximab Medical J1602 Simponi/golimumab Anti-inflammatory Medical J3357 Stelara/ustekinumab Anti-inflammatory Medical
9 J7321 Supartz Medical J7325 Synvisc One Medical J7325 Synvisc/Hylan Medical J2323 Tysabri Anti-inflammatory Medical J9303 Vectibix Panitumumab Medical J1562 Vivaglobin Medical J3385 VPRIV/Velaglucerase Alfa Enzymes Medical J2357 Xolair omalizumab Medical J9228 Yervoy ipilimumab Medical J0256 Zemaira*/alpha 1 proteinase Alpha-1 Medical
Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationMedStar Medicare Choice Pharmacy Services
Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationSPECIALTY PHARMACY Master Clinical Drug List
Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None
More informationAetna Better Health. Specialty Drug Program
Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid
More informationBCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015
Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests
More informationSpecialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs
Specialty Drugs The following is a list of medications that are considered to be specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationSpecialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time.
Specialty Drugs The following is a list of medications that are considered specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications that
More informationRAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More information2017 MDwise HIP Medical Services that Require Prior Authorization
2017 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More information2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017
Abstral Actemra Adcirca Adempas Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio Beleodaq
More information2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018
Abstral Actemra Adcirca Adempas Aliqopa Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio
More information2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization
2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services
More informationSpecialty Drug List - Sorted by Therapeutic Class Developed for the Mississippi Division of Medicaid by Mercer
ANTI-INFECTIVE ABELCET 100 MG/20 ML VIAL 4/1/2017 ANTI-INFECTIVE AMBISOME 50 MG VIAL 4/1/2017 ANTI-INFECTIVE ANCOBON 250 MG CAPSULE 4/1/2017 ANTI-INFECTIVE ANCOBON 500 MG CAPSULE 4/1/2017 ANTI-INFECTIVE
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More information2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization
2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services
More informationLIMITED DISTRIBUTION MEDICATIONS
ACTEMRA IV (USSC can dispense 162 mg PFS) ACTHAR HP ACTIMMUNE ADAGEN ADCETRIS CVS Specialty 1-800-237-2767 1-800-237-2767 ADEMPAS ADVATE ALDURAZYME ALECENSA ALIQOPA ALUNBRIG AMPYRA APOKYN ARALAST NP ARCALYST
More informationPercent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle
Department of General Services Procurement Division Contract # 01-14- 65-57 Pharmaceutical Acquisitions Section Exhibit G-1 April 30, 2015 Walgreens Specialty Pharmacy LLC, Products Pricing Crescent Healthcare,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationacromegaly Drugs Covered Uses Exclusion Criteria Required Medical Information Age Restriction Prescriber Restriction Coverage Duration
acromegaly SIGNIFOR, SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML, SOMAVERT SUBCUTANEOUS RECON SOLN 15 MG, 20 MG, 25 MG, 30 MG All medically accepted indications not
More informationDRUGS REQUIRING PRIOR AUTHORIZATION
DRUGS REQUIRING PRIOR AUTHORIZATION Medication Abstral Actemra Acthar Gel Actiq* Adcirca Adderall Adderall XR Addyi Adempas Adipex* Adzenys XR-ODT Afinitor Afinitor Alecensa Alecensa Ampyra Androderm AndroGel
More information2016 MDwise HIP Medical Services that Require Prior Authorization
2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More information2018 MDwise HIP Medical Services that Require Prior Authorization
2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More information2018 MDwise HIP Medical Services that Require Prior Authorization
2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More information2018 MDwise HIP Medical Services that Require Prior Authorization
2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More informationInjections Requiring Prior Authorization
At VIVA Health, we strive to keep our provider network informed of any changes. Most of you may currently obtain prior authorizations for administered injections. Below is a list of injection, infusion,
More informationOPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC
OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC 1 Conflicts of Interest Damon Hostin Has no real or apparent conflicts
More informationPA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116
More informationLista de medicamentos especializados
Lista de medicamentos especializados Vigencia: 1o. de enero de 2016 A continuación se listan, en orden alfabético, los medicamentos de especialidad recetados más frecuentemente. Los medicamentos de especialidad
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 9: Issue 27 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationMETABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
More informationDrug Name Generic Name J-Code Unclassified Drugs in excess of $10,000
Unclassified Drugs in excess of $10,000 J3490 Unclassified Biologics in excess of $10,000 J3590 Revenue Codes in excess of $10,000 R250 - R259 ABRAXANE paclitaxel protein-bound J9264 & J9267 ACTEMRA tocilizumab
More informationOriginal Policy Date
MP 5.01.17 Specialty Drugs Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/ Date Local policy Last updated/12:2013 Return to Medical Policy Index
More informationSELF-ADMINISTERED MEDICATIONS LIST
SELF-ADMINISTERED MEDICATIONS LIST Table of Contents Page Last Updated: January 23, 2019 INSTRUCTIONS FOR USE... 1 APPLICABLE CODES... 1 Related Commercial Policy LIST HISTORY/REVISION INFORMATION... 5
More information2016 MDwise HIP Medical Services that Require Prior Authorization
2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Coding All Out of Network services Facility to facility ambulance transport
More informationMDwise Hoosier Care Connect Medical Services that Require Prior Authorization
MDwise Hoosier Care Connect Medical Services that Require Prior Authorization Certain Indiana Health Coverage Programs (IHCP) services require prior authorization (PA) for members enrolled in the Hoosier
More informationINJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions
J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationSUPPLEMENTARY INFORMATION
Table S1 Therapeutic biologic product approvals, classes and innovation categories: 16 24 Approval year Trade name Active Ingredient(s) Drug class Innovation category Approval date 16 Intron-A Interferon
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationPA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0373T H2020 96116 96112 96113 96121 96130 96131
More informationOverview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)
Overview of Cancer Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org What is Cancer? A collection of related diseases in which some of the body s cells begin to divide abnormally
More informationBCN Advantage SM requirements for drugs covered under the medical benefit
J0586 ABOBOTULINUMTOXINA Dysport X X X the medication is being used to treat J0178 AFLIBERCEPT Eylea X X X X X of Neovascular (Wet) -Related Macular Degeneration of Macular Edema following either central
More informationPrescription Drug Benefit Rider V
Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationPulmonary Hypertension Weight Loss Skin Conditions. Skin Conditions Multiple Sclerosis Endocrine Disorder. Endocrine Disorder.
Prior Authorization PricewaterhouseCoopers The following medications may require prior authorization prior to dispensing at a participating retail pharmacy or through the Express Scripts Pharmacy home
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationPrescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationMDwise HIP Prior Authorization and Drug List
MDwise HIP Prior Authorization and Drug List Services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services With the exception of ER, Ambulance, Urgent Care Center
More informationChemotherapy 101 for Radiation Oncology Workers
Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent
More informationCriteria for Medical Benefit Drugs Requiring Clinical Review
Note: Authorization of a service based on the clinical information provided does not guarantee payment. The claim must be properly submitted and the member must be eligible on the date of service for the
More informationPremium prior authorization
Premium prior authorization Some medications must be authorized for coverage because they re only approved or effective in treating specific illnesses, they cost more or they may be prescribed for conditions
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationafter reconstitution No Yes Refrigerate; do Not freeze. Discard unused portions; do Not save for further Immune Deficiencies & Related
Store at room temp. Protect from bright light. Freezing or refrigerating do not adversely affect the stability of intact vials. Different standards apply Abraxane Oncology- Injectable IV No No Yes after
More informationClinical UM Guidelines for Indiana, Kentucky, Missouri, Ohio and Wisconsin
10/4/2018 State: State CG number CG title CG Category Date implemented CG-ADMIN-02 Clinically Equivalent Cost Effective Services Targeted Immune Modulators Admin 7/1/2018 CG-ANC-04 Ambulance services Air
More informationExclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or
Noridian Healthcare Solutions, LLC Jurisdiction F Part B Self-Administered Drug (SAD) Exclusion List (A53033); Effective 8/7/2017 The following medications are considered self-administered and are not
More informationCriteria for Medical Benefit Drugs Requiring Clinical Review
Note: Authorization of a service based on the clinical information provided does not guarantee payment. The claim must be properly submitted and the member must be eligible on the date of service for the
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 17: Issue 34 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationInjectable Drugs Requiring Pre-Service Approval
Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients
More informationRe: Integrated Oncology Management Program with evicore healthcare: Update on codes requiring precertification
Ajani Nimmagadda, MD Senior Medical Director , , Re: Integrated Oncology Management Program with evicore
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationSelect Prior Authorization
Select Prior Authorization Some medications must be authorized for coverage because they re only approved or effective in treating specific illnesses, they cost more or they may be prescribed for conditions
More informationACAMPROSATE (CAMPRAL)
ACAMPROSATE (CAMPRAL) ACAMPROSATE CALCIUM Creatinine clearance less than 30 PAGE 1 LAST UPDATED 06/2016 ADALIMUMAB (HUMIRA) HUMIRA, HUMIRA PEDIATRIC CROHN'S, HUMIRA PEN, HUMIRA PEN CROHN'S-UC-HS, HUMIRA
More informationLIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT
LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion
More informationMedical Prior Authorization List Rosen Employee Plans For prescription drug requirements, contact EHIM toll-free at
For prescription drug requirements, contact EHIM toll-free at 1.800.311.3446. General Information These requirements are administered by Health First Health Plans ( Health Plan ). Benefits are determined
More informationState: Virginia. Clinical Guidelines Applicable for Virginia
State: Virginia Clinical Guidelines Applicable for Virginia NOTE: Any Clinical Guideline not included in this standard adopted list that is needed to complete a ASO group-specific review requirement will
More informationSelect Prior Authorization
Select Prior Authorization Some medications must be authorized for coverage because they re only approved or effective in treating specific illnesses, they cost more or they may be prescribed for conditions
More informationSpecial Notes Implementation Date by CO. State CG number CG title CG Category Original Current Version
Anthem Blue Cross and Blue Shield Approved and adopted corporate Clinical Utilization Management (UM) Guidelines COLORADO Updated August 17, 2018 NOTE: Any Clinical Guideline not included in this standard
More informationSpecialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > September 2015 Specialty Pipeline Update New Drug Information Xuriden (uridine triacetate): The Food and Drug Administration (FDA) approved Wellstat Therapeutics oral
More informationPharmacy Medical Necessity Guidelines: Oral Cancer Medications
Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationUtilization Management
Abraxane Abraxane Actemra (IV) Inflammatory Conditions PA/Step Actemra (SQ) Inflammatory Conditions PA/Step Acthar HP Miscellaneous CNS Disorders PA Actimmune NF Adcetris Adcirca Adempas Advate (all forms)
More informationFormulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy
More informationJ-Code Trade Name Drug Name Required Medical Information
FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES Updated: 10/31/2017 J-Code Prior Authorizations & Required Clinical Information Medicaid, Child Health Plus, HealthierLife, Metal-Level J-Code Trade
More informationBuckeye Health Plan (MMP) 2016 Prior Authorization Criteria
Buckeye Health Plan (MMP) 2016 Prior Authorization Instructions: 1. With this file, at the top, click Edit, then click Find. 2. In the Find box type the name of the medication you want to find. 3. Click
More informationSpecialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > December 2015 Specialty Pipeline Update New Drug Information Alecensa (alectinib): The Food and Drug Administration (FDA) approved Genentech s orally administered ALK
More informationSpecialty Pipeline Update
Specialty Pipeline Update D Drug Insights > March 2016 New drug information Odefsey (emtricitabine, tenofovir alafenamide, rilpivirine): The Food and Drug Administration (FDA) approved Gilead s combination
More informationSelect Prior Authorization
Select Prior Authorization Some medications must be authorized for coverage because they re only approved or effective in treating specific illnesses, they cost more or they may be prescribed for conditions
More informationALPHA1-PROTEINASE INHIBITOR
Ally Rx D-SNP Current as of Nov. 1, 2018 ALPHA1-PROTEINASE INHIBITOR ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG GLASSIA PROLASTIN-C INTRAVENOUS RECON SOLN ZEMAIRA PA Documentation of diagnosis, lab results,
More informationCPT Service Description Effective Date
Medical Oncology Program Review Code List 2 nd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April,
More informationFIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11)
FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11) Brand Generic J Code Covered Uses Required Medical Information and
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Oncology Agents Rx.01.67 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some
More informationLDI integrated pharmacy services
8 ARRANON CARIMUNE NF Immunodeficiency 8-MOP Psoriasis ARZERRA CAYSTON Cystic Fibrosis A ASTAGRAF XL Antirejection CERDELGA Gaucher's Disease abacavir ATRIPLA CEREZYME Gaucher's Disease abacavir/lamivudine/
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationPrior Authorization Program
Prescription Drug List January 2011 Prior Authorization Program The prior authorization program helps us offer broad prescription drug coverage and promotes safe, clinically appropriate drug usage. Under
More informationPharmacy Services Request Types
FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare
More informationINJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]
Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationSpecialty Overview by Prior Authorization Approval or Denial 4th Quarter 2016
Specialty Overview by Prior Authorization Approval or 4th Quarter 2016 Carrier Physician Specialty Drug Drug Class Decision Comments Reporting Year Reporting Month 3961 GASTROENTEROLOGY Humira RHEUMATOID
More informationPan-Canadian Pharmaceutical Alliance: Completed Negotiations
Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of November 30, 2017 188 joint negotiations have been completed** for the following drugs and indications: Drug Product Abilify Maintena
More informationSpecialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016
Specialty Overview by Prior Authorization Approval or 2nd Quarter 2016 3961 DERMATOLOGY Humira RHEUMATOID ARTHRITIS Approval Approved from 04/13/2016 thru 04/13/2018 3961 DERMATOLOGY Stelara PSORIASIS
More information